Table 1.
Clinicopathological data of patient-derived neuroblastoma tissue and warm autopsy-derived non-neoplastic tissue.
| Tissue for Biochemical Analyses (n = 17) |
NB Tissue for IHC Analyses (n = 36) |
NNT for IHC and Biochemical Analyses (n = 18) |
|
|---|---|---|---|
| Age (Median) | 15 m | 27 m | 61 y |
| Gender | |||
| Female | 7 (41%) | 15 (42%) | 4 (22%) |
| Male | 10 (59%) | 21 (58%) | 14 (78%) |
| Stage | |||
| 1 | 1 (6%) | 5 (14%) | |
| 2 | 3 (18%) | 4 (11%) | |
| 3 | 4 (24%) | 13 (36%) | |
| 4 | 3 (18%) | 12 (33%) | |
| 5 | 0 (0%) | 2 (6%) | |
| Unknown | 6 (35%) | 0 (0%) | |
| MYCN Status | |||
| Non-amplified | 13 (76%) | 26 (72%) | |
| Amplified | 2 (12%) | 10 (28%) | |
| Gain | 1 (6%) | 0 (0%) | |
| Unknown | 1 (6%) | 0 (0%) | |
| Localization | |||
| Adrenal gland | 4 (24%) | 20 (56%) | |
| Retroperitoneal | 1 (6%) | 8 (22%) | |
| Mediastinal | 0 (0%) | 8 (22%) | |
| Abdominal | 3 (18%) | 0 (0%) | |
| Thoracic | 4 (24%) | 0 (0%) | 9 (50%) |
| Others | 5 (29%) | 0 (0%) | |
| Temporal lobe | 0 (0%) | 0 (0%) | 9 (50%) |
| Diagnosis | |||
| Ganglioneuroma | 0 (0%) | 4 (11%) | |
| Ganglioneuroblastoma | 6 (35%) | 5 (14%) | |
| Neuroblastoma | 11 (65%) | 27 (75%) | |
| Differentiated | n.d. | 13 (48%) | |
| Poorly differentiated | n.d. | 12 (44%) | |
| Undifferentiated | n.d. | 2 (7%) |
m = months; y = years; n.d., not defined; NB = neuroblastoma; NNT = non-neoplastic tissue, IHC = immunohistochemical.